Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BR-TD-1001 immunogenicity and safety in healthy children
NCT04618939Phase 3Completed
- Sponsor
- Boryung Biopharma
- Start
- Oct 2016
- Primary completion
- Apr 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of BR-TD-1001 in diphtheria and Tetanus (2 arms), sponsored by Boryung Biopharma. Primary endpoint: Seroprotection rate of anti-diphtheria toxoid (DT) and anti-tetanus toxoid (TT) at 28 days. Started Oct 2016; status: completed.
02
Drugs
BR-TD-1001
03
Conditions
diphtheriaTetanus
Beyond the preview
Go deeper on NCT04618939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04618939.